|
|
- Addition of a randomised comparison study, in a partial factorial design, nested within the master TICH-3 protocol. The comparison will enable a multicentre, randomised phase III superiority trial of desmopressin (DASH-2) for patient with ICH who are taking antiplatelets, only applicable to UK sites.
- Addition of Associate Professor Mike Desborough as co-lead to oversee DASH-2.
- Addition of electronic Microsoft Form versions of day 180 follow-up and resource use questionnaire so that participants can complete them electronically (as opposed to postally or over the telephone), if they prefer.
|
